Thursday August 28, 4:00 pm ET MORRIS PLAINS, N.J., Aug. 28, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NasdaqGM:IMMU - News ), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported revenues of $1.0 million and a net loss of $6.9 million, or $0.09 per share, for the fourth quarter of fiscal year 2008, which ended June 30, 2008. This...
[read full story]